清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

医学 伦瓦提尼 舒尼替尼 临床终点 肾细胞癌 危险系数 内科学 彭布罗利珠单抗 中止 临床研究阶段 肿瘤科 临床试验 置信区间 索拉非尼 癌症 免疫疗法 肝细胞癌
作者
Robert J. Motzer,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,B. Yа. Alekseev,Sun Young Rha,Jaime R. Merchan,Jeffrey C. Goh,Aly‐Khan A. Lalani,Ugo De Giorgi,Bohuslav Melichar,Sung‐Hoo Hong,Howard Gurney,María José Méndez-Vidal,Evgeny Kopyltsov,Sergei Tjulandin,Teresa Alonso‐Gordoa,Vadim Kozlov,Anna Alyasova,Eric Winquist,Pablo Maroto,Miso Kim,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Karla Rodriguez-Lopez,Joseph E. Burgents,Cixin He,Chinyere E. Okpara,Jodi A. McKenzie,Toni K. Choueiri,Robert J. Motzer,Toni K. Choueiri,Thomas E. Hutson,Luke T. Nordquist,David R. Spigel,Jaime R. Merchan,Saby George,Sandhya Srinivas,Brendan D. Curti,Andrew Pippas,Elisabeth I. Heath,Subramanya Rao,Theodore Stewart Gourdin,Mehmood Hashmi,Nafisa Burhani,Ana M. Molina,Alan J. Koletsky,Robert S. Alter,C. Alemany,Benjamin A. Gartrell,Mike Cusnir,Harsha Vyas,Stephanie L. Graff,Christian Squillante,Mark Knapp,Ivor Percent,Vijay Patel,Daniel L. Spitz,C. Harkness,Marc Matrana,Lindsay Overton,Stephen Richey,Donald Richards,Habib M. Ghaddar,Robert Galamaga,Ralph J. Hauke,Joseph Haggerty,Ronald Harris,Mark Johns,Samith T. Kochuparambil,Christian Kollmannsberger,Bobby Shayegan,Christina Canil,Eric Winquist,Catherine Sperlich,Georg A. Bjarnason,Naveen S. Basappa,Wolfgang Loidl,Wolfgang Horninger,Manuela Schmidinger,Lionel D’Hondt,Dirk Schrijvers,Annemie Rutten,Peter Schatteman,Wim Wynendaele,Daisy Luyten,Spyridon Sideris,Christine Gennigens,Bohuslav Melichar,Jana Katolická,Jiří Tomášek,Jana Prausová,Tomáš Büchler,Petra Holečková,Philippe Barthélémy,Diégo Tosi,Baptiste Abbar,Sylvie Négrier,Stéphane Oudard,Éric Voog,Sylvie Zanetta,Frédéric Rolland,Jens Bedke,Stefan Siemer,Manfred Wirth,Jan Schleicher,Maria De Santis,Lothar Bergmann,Michael Staehler,Philipp Ivanyi,Christoph Lutz,Gunhild von Amsberg,Martin Boegemann,Uwe Zimmermann,Ray McDermott,Richard Bambury,Paul Donnellan,Oscar S. Breathnach,Raya Leibowitz‐Amit,Olesya Goldman,Avivit Peer,David Sarid,Hovav Nechushtan,Raanan Berger,Victoria Neiman,Fabio Calabrò,Paolo Pedrazzoli,Francesco Boccardo,Alketa Hamzaj,Ferdinando Riccardi,Ugo De Giorgi,Sandro Pignata,Sandra Santarossa,Francesco Massari,Giuseppe Tonini,Caterina Accettura,Francesco Carrozza,Roberto Sabbatini,Elena Verzoni,Elisa Biscaldi,Britt B. M. Suelmann,Alfons J.M. van den Eertwegh,H.V. van Thienen,Ewa Kalinka‐Warzocha,Jacek Jassem,Violetta Sulżyc‐Bielicka,Sławomir Mańdziuk,Sergei Tjulandin,Oleg Karyakin,Anna Alyasova,B. Yа. Alekseev,Alexander Zyrianov,В. Б. Матвеев,Evgeny Kopyltsov,Vadim Kozlov,José Ángel Arranz Arija,Pablo Borrega García,Miguel Á. Climent Durán,Begoña P. Valderrama,Emilio Esteban,Francisco Javier Garcia del Muro Solans,Jesus Garcia-Donas Jimenez,Teresa Alonso‐Gordoa,J.P. Maroto Rey,B. Mellado González,M.J. Méndez Vidal,Javier Puente,C. Suárez Rodríguez,Enrique Grande Pulido,Guillermo Crespo,Natalia Fernandez Nuñez,Ignacio Durán Martínez,J. Beyer,Natalie Fischer,Hilary Glen,Ricky Frazer,Jennifer Allison,Thomas Powles,Jahangeer Malik,Christy Ralph,Sarah Rudman,T. Geldart,Aristotelis Bamias,Sofia Baka,V. Georgoulias,Konstantinos Papazisis,Haralabos P. Kalofonos,Eleni Timotheadou,Seok‐Soo Byun,Bumjin Lim,Sun Young Rha,Seong Il Seo,Jinsoo Chung,Miso Kim,Sung‐Hoo Hong,Jae‐Lyun Lee,Se Hoon Park,Tae Gyun Kwon,Ian D. Davis,Shirley Wong,Ian Byard,Andrew Weickhardt,Howard Gurney,Jeffrey C. Goh,Takahiro Osawa,Naoya Masumori,Shingo Hatakeyama,Mitsuru Saito,Yoshihiko Tomita,Yuji Miura,Masayoshi Nagata,Go Kimura,Mototsugu Oya,Toshio Takagi,Yu Nakamura,Hisashi Hasumi,Masatsugu Iwamura,Akira Komiya,Atsushi Komaru,Masafumi Oyama,Yoshihisa Matsukawa,Norihito Soga,Minoru Kato,Masahiro Nozawa,Makito Miyake,Yuzo Nakano,Kohei Edamura,Nobuyuki Hinata,Homare Okazoe,Masayuki Takahashi,Masatoshi Eto,Kojiro Oba,Takeshi Kishida,Osamu Ukimura
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (11): 1222-1228 被引量:37
标识
DOI:10.1200/jco.23.01569
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2 weeks off]). At this data cutoff date (July 31, 2022), the OS hazard ratio (HR) was 0.79 (95% CI, 0.63 to 0.99). The median OS (95% CI) was 53.7 months (95% CI, 48.7 to not estimable [NE]) with lenvatinib plus pembrolizumab versus 54.3 months (95% CI, 40.9 to NE) with sunitinib; 36-month OS rates (95% CI) were 66.4% (95% CI, 61.1 to 71.2) and 60.2% (95% CI, 54.6 to 65.2), respectively. The median progression-free survival (95% CI) was 23.9 months (95% CI, 20.8 to 27.7) with lenvatinib plus pembrolizumab and 9.2 months (95% CI, 6.0 to 11.0) with sunitinib (HR, 0.47 [95% CI, 0.38 to 0.57]). Objective response rate also favored the combination over sunitinib (71.3% v 36.7%; relative risk 1.94 [95% CI, 1.67 to 2.26]). Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-naïve patients with aRCC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aaronroseman完成签到 ,获得积分10
22秒前
jkaaa完成签到,获得积分10
24秒前
herpes完成签到 ,获得积分10
24秒前
Lz555完成签到 ,获得积分10
29秒前
沉静大雁应助livra1058采纳,获得10
41秒前
tcy完成签到,获得积分10
43秒前
hu完成签到 ,获得积分10
45秒前
zxq完成签到 ,获得积分10
56秒前
汤大侠完成签到,获得积分10
1分钟前
在水一方应助冒险寻羊采纳,获得10
1分钟前
cq_2完成签到,获得积分0
1分钟前
prrrratt完成签到,获得积分10
1分钟前
tingting完成签到,获得积分10
1分钟前
CGBIO完成签到,获得积分10
1分钟前
真的OK完成签到,获得积分0
1分钟前
cityhunter7777完成签到,获得积分10
1分钟前
阳光完成签到,获得积分10
1分钟前
朝夕之晖完成签到,获得积分10
1分钟前
675完成签到,获得积分10
1分钟前
BMG完成签到,获得积分10
1分钟前
王jyk完成签到,获得积分10
1分钟前
guoyufan完成签到,获得积分10
1分钟前
洋芋饭饭完成签到,获得积分10
1分钟前
喜喜完成签到,获得积分10
1分钟前
qq完成签到,获得积分10
1分钟前
ys1008完成签到,获得积分10
1分钟前
zwzw完成签到,获得积分10
1分钟前
美满惜寒完成签到,获得积分10
1分钟前
Temperature完成签到,获得积分10
1分钟前
呵呵哒完成签到,获得积分10
1分钟前
清水完成签到,获得积分10
1分钟前
alanbike完成签到,获得积分10
1分钟前
qvb完成签到 ,获得积分10
1分钟前
1分钟前
王伟轩应助明天会更美好采纳,获得10
2分钟前
livra1058完成签到,获得积分10
2分钟前
简单567应助明天会更美好采纳,获得10
2分钟前
石头完成签到,获得积分10
2分钟前
2分钟前
J_Xu完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Social Cognition: Understanding People and Events 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6028277
求助须知:如何正确求助?哪些是违规求助? 7688022
关于积分的说明 16186305
捐赠科研通 5175474
什么是DOI,文献DOI怎么找? 2769510
邀请新用户注册赠送积分活动 1752962
关于科研通互助平台的介绍 1638757